Sure, but what does that tell you about their confidence in this lawsuit?
This is not Hikma's first rodeo. They get sued all the time. It is literally part of their business model. They have over 800 products they sell, do nearly $3B in revenue, have a market cap of $5.5B, and I doubt they are that worried about Amarin. If they were, they would have withdrawn from selling IPE.
And even if Amarin is somehow still around in 4 or 5 years, and happens to win the appeal of the appeal, they then have a protracted fight about the damages. And there will be extensive analysis of how to arrive at "lost profits" for Amarin. And this process will drag on for years.
Look at GSK vs. Teva. Very similar case. Filed in 2014, still ongoing to this day. They're actually talking about a potential new trial. https://casetext.com/case/glaxosmithkline-llc-v-teva-pharm-us-3 . Amarin's case was only filed in 2020. How much money do you think GSK has spent on this trial? And Teva? And do you think Hikma can outlast Amarin?
The company is going to be sold long before this lawsuit ever has any impact on Amarin. A final, post-appeal decision is at least 4 years away. The only thing happening right now is lawyers getting rich.
I know others see it differently, and that is fine. I'm more concerned with Amarin's actual operations, not in a lawsuit that will likely never amount to anything meaningful for Amarin.
Market Data 
Markets 
AI
